Bruce Turner, M.D., Ph.D.

Chief Strategy Officer and Interim Chief Financial Officer

Dr. Turner previously founded several biotechnology companies including Xanadu Bio and Gennao Bio, where he has served in executive positions including Chief Executive Officer and President. During his tenure at these companies and others he has successfully raised more than $100M of financing despite challenging market conditions. Dr. Turner previously spent 5 years at Hoffman La-Roche with increasing responsibility for drug development in the areas of metabolic diseases and oncology. Recently, Dr. Turner was a managing director at Boxer Capital of the Tavistock Group and Bank of American Merrill Lynch. Dr. Turner is the author of more than 40 publications primarily in areas of breast cancer and signal transduction. He completed his undergraduate education at the University of Chicago and graduated from University of Pennsylvania School of Medicine with M.D and Ph.D. degrees. Dr. Turner completed a residency in Radiation Oncology at Yale University.